Cavutilide
CAS No. 1276186-19-6
Cavutilide( —— )
Catalog No. M35602 CAS No. 1276186-19-6
Cavutilide has antiarrhythmic activity, inhibits hERG K(+) channels, and can be used to study heart failure and persistent atrial fibrillation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCavutilide
-
NoteResearch use only, not for human use.
-
Brief DescriptionCavutilide has antiarrhythmic activity, inhibits hERG K(+) channels, and can be used to study heart failure and persistent atrial fibrillation.
-
DescriptionCavutilide, benzamide, is used as an antiarrhythmic, antiarythmique.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1276186-19-6
-
Formula Weight399.458
-
Molecular FormulaC22H26FN3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCN1CCC(CC(c(cc2)ccc2F)NC(c(cc2)ccc2[N+]([O-])=O)=O)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. WHO Drug Information, Vol. 36, No. 2, 2022.
molnova catalog
related products
-
Panitumumab
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
-
Befotertinib
Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
Oritinib
Oritinib is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (d746-750), EGFR (d746-750/T790M), respectively. Oritinib can be used in studies about the treatment of non-small cell lung cancer.
Cart
sales@molnova.com